胰高血糖素样肽-1受体激动剂治疗非酒精性脂肪性肝病的研究进展  

Glucagon-like peptide-1 receptor agonists in the treatment of non-alcoholic fatty liver disease:research advances

作　　者：张丽[1] 李慕鹏 樊莲莲[1] 沈珍 申屠建中 ZHANG Li;LI Mu-peng;FAN Lian-lian;SHEN Zhen;SHEN-TU Jian-zhong(Phase 1 Clinical Trial Center,People′s Hospital of Deyang City,Deyang 618000,China)

机构地区：[1]德阳市人民医院1期临床研究中心,德阳618000

出　　处：《国际药学研究杂志》2020年第3期169-174,187,共7页Journal of International Pharmaceutical Research

基　　金：德阳市科技计划项目(2019SZ038)。

摘　　要：非酒精性脂肪性肝病(NAFLD)是全球最常见的慢性肝病。NAFLD主要包括非酒精性脂肪肝(NAFL)和非酒精性脂肪性肝炎(NASH),其中NASH可能进展为肝硬化和肝细胞癌。肥胖和2型糖尿病(T2DM)是NAFLD的重要危险因素。胰岛素抵抗(IR)是NAFLD和T2DM共同的关键发病机制之一。胰高血糖素样肽-1受体激动剂(GLP-1 RA)能改善IR、降低血糖与血脂、减轻体质量,已获批用于治疗T2DM和肥胖症。鉴于NAFLD目前尚无特异性的治疗药物,而GLP-1 RA可改善其IR、减少肝脂肪变性、改善肝纤维化,因此GLP-1 RA对于NAFLD合并T2DM的治疗具有重要意义。本文对GLP-1 RA治疗NAFLD的可能机制及其临床研究进展进行综述。Non-alcoholic fatty liver disease(NAFLD)is the most common chronic liver disease worldwide.NAFLD mainly includes non-alcoholic fatty liver(NAFL)and non-alcoholic steatohepatitis(NASH).NASH may progress to hepatic cirrhosis and hepatocellular carcinoma.Obesity and type 2 diabetes(T2DM)are important risk factors for NAFLD.Insulin resistance(IR)is one of the key pathogenesis of NAFLD and T2DM.Glucagon-like peptide-1 receptor agonist(GLP-1 RA)has been shown to improve insulin resistance,lower blood sugar and lipids,and reduce body mass.GLP-1 RA has been approved for treatment of T2DM and obesity.There is currently no specific therapeutic drug for NAFLD.GLP-1 RA can improve IR,reduce liver steatosis,and improve liver fibrosis.Therefore,GLP-1 RA is one of great significance for the treatment of NAFLD combined with T2DM.This review summarizes the possible mechanism and clinical research progress in GLP-1 RA for NAFLD treatment.

关 键 词：胰高血糖素样肽-1受体激动剂 非酒精性脂肪性肝病 胰岛素抵抗 

分 类 号：R915[医药卫生—微生物与生化药学]